In a previously published study, the authors randomized 108 adult patients with a malignant hematologic disorder undergoing allogeneic bone marrow transplantation from a human leukocyte antigen-identical sibling to receive methylprednisolone (53 patients; MP1) or not to receive methylprednisolone (55 patients; MP-) as a part of graft-versus-host disease (GVHD) prophylaxis. All patients received cyclosporine and methotrexate. The cumulative incidence of acute GVHD was found to be significantly lower among the patients given MP. METHODS: In the current study, the authors performed a long-term follow-up to discover possible late effects of the intensified GVHD prophylaxis. RESULTS: The median follow-up for surviving patients was 24.5 years. In the MP1 group, the overall survival and recurrence-free survival were higher (P 5 .021 and P 5 .028, respectively) and the nonrecurrence mortality was lower (P 5 .003) than in the MP-group. There was a trend toward a lower cumulative incidence and a significantly lower prevalence (P 5 .031) of chronic GVHD in the MP1 group. There was no difference noted with regard to the rate of disease recurrence or in the incidence of secondary malignancies. Eleven patients in the MP-group but none in the MP1 group died >15 years after transplantation. At the end of follow-up, the overall survival rates in the MP1 and MP-groups were 55% and 20%, respectively, and the recurrence-free survival rates were 49% and 15%, respectively. CONCLUSIONS: Long-term survival was found to be higher among the patients given MP in addition to cyclosporine and methotrexate. There was marked late nonrecurrence mortality observed in the group not given MP. No adverse late effects caused by the addition of corticosteroid were observed. Cancer 2018;124:727-33.
INTRODUCTION
Graft-versus-host disease (GVHD) and its consequences are the most significant complication of allogeneic hematopoietic stem cell transplantation, and the prevention and treatment of GVHD are crucial for the success of this form of treatment. A calcineurin inhibitor in combination with a short course of methotrexate or mycophenolate mofetil is the most common form of GVHD prophylaxis. Corticosteroids are the first-line treatment of acute GVHD, but their role in prophylaxis is not well established. Corticosteroids have been used for the prophylaxis of GVHD with cyclosporine, tacrolimus, methotrexate, mycophenolate mofetil, cyclophosphamide, antilymphocyte globulin, and monoclonal ricin-combined or other antibodies in various combinations. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Studies regarding the effect of the addition of corticosteroids to the combination of cyclosporine and a short course of methotrexate have shown inconsistent results, with some demonstrating an increase in acute GVHD 12 whereas in others no effect was noted 13 or the onset was delayed. 14 In our previous study, 15 the addition of methylprednisolone (MP) resulted in a significantly reduced incidence of acute GVHD, shorter hospitalization, and fewer infections, as well as a clear trend toward a lower incidence of chronic GVHD among low-risk patients. There were no differences noted with regard to the rate of disease recurrence or survival. Herein, we performed a long-term follow-up of our previous study to discover possible late effects of the intensified GVHD prophylaxis.
MATERIALS AND METHODS
A total of 108 consecutive adult patients who were treated for a malignant hematologic disorder with allogeneic bone marrow transplantation from a human leukocyte antigen-identical sibling donor at Helsinki University Hospital were entered into the study from 1989 to 1994. The characteristics of the patients and donors are shown in Table 1 . 15 There were no significant differences noted between the study groups. Histocompatibility typing of the donors and recipients was performed by serology. As conditioning treatment for transplantation, the patients received cyclophosphamide at a dose of 60 mg/kg 3 2 and total body irradiation of 6 3 2 grays or busulfan at a dose of 16 mg/kg in 4 days. 15 All patients received a bone marrow graft. The grafts were nonmanipulated with the exception of the removal of red cells and plasma in case of ABO incompatibility.
Postgrafting immunosuppression consisted of cyclosporine and methotrexate with or without MP according to randomization. Cyclosporine was initiated on the day before transplantation and given at a dose of 3 mg/kg/ day as a continuous intravenous infusion. This was continued until approximately 2 weeks after transplantation, when the patient was able to take the drug by mouth. The oral dose was 3 mg/kg/day taken in 2 parts at 12-hour intervals. This dose was modified in the case of adverse effects and to keep the whole-blood cyclosporine concentration <200 lg/L. Cyclosporine administration was continued until 1 year after transplantation and then tapered off in approximately 6 weeks.
Methotrexate was administrated intravenously at a dose of 15 mg/m 2 of the body surface area intravenously on day 1 and at 10 mg/m 2 on days 3, 6, and 11 after infusion of the graft. Six hours after each dose of methotrexate, the same dose in milligrams of calcium folinate was given intravenously.
A total of 53 patients were randomized to receive MP (MP1) and 55 were randomized not to receive MP (MP-). The schedule of MP administration is shown in Table 2 . The drug was given orally.
Acute and chronic GVHD were graded according to previously published criteria [16] [17] [18] [19] as detailed in the original report. 15 Acute GVHD was treated at the time of its appearance, independent of the grade, with 10 mg/kg/day of MP divided into 4 doses intravenously. The dose was halved every 3 days 3 times and thereafter tapered according to the clinical situation. In corticosteroid-resistant cases, antilymphocyte globulin (Atgam; Upjohn, Kalamazoo, Michigan) was used as second-line treatment. The treatment of chronic GVHD consisted of MP and, according to individual judgment, cyclosporine, thalidomide, psoralen plus ultraviolet A, and low-dose irradiation of the lymph nodes.
The patients were systematically followed at the transplantation center for 10 years after the transplantation. Thereafter, health information was obtained by a combination of less regular visits to the transplantation center, questionnaire letters and telephone calls to the patient, and records from local hospitals. For the analyses of chronic GVHD, data from the first 10 years with systematic follow-up at the transplantation center were used. At the time of the follow-up closure for the current study, the survival of the patients was confirmed from the national population registry.
Statistical Analysis
The cumulative risk of chronic GVHD, risk of disease recurrence, and overall and recurrence-free survival were Original Article analyzed using Kaplan-Meier curves and log-rank statistics with SPSS statistical software (version 22.0; IBM Corporation, Armonk, NY). Only patients who survived at least 100 days after transplantation were included in the analysis of chronic GVHD. No patient with signs of chronic GVHD died before day 100. Overall survival was calculated from the time of transplantation to death from any cause and recurrence-free survival was calculated from the time of transplantation to disease recurrence or death. Recurrence of acute leukemia was defined as >5% blasts in an essentially normocellular bone marrow. Recurrence of chronic myeloid leukemia included both hematologic and cytogenetic recurrences. Disease progression after the achievement of a minimal disease state of myeloma, lymphoma, or chronic lymphatic leukemia after transplantation was also included in the analysis of the risk of disease recurrence. Differences in the prevalence of chronic GVHD during the follow-up were modeled using a hierarchical model (mixed model).
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Both follow-up and treatment (MP1 vs MP-) were used as fixed factors. The identity of the patient was used as a random factor and its effect was modeled as a random intercept in the fitted model. All mixed models were fitted in the R software version 3.3 21 using the extension package nlme version 3.1-128. 22 
RESULTS
The median follow-up for surviving patients was 24.5 years (range, 22.7-26.9 years). In the MP1 group, the overall survival (P 5 .021) (Fig. 1) and recurrence-free survival (P 5 .028) (Fig. 2) were significantly higher and the nonrecurrence mortality (Fig. 3 ) was lower (P 5 .003) compared with the MP-group. There was no difference noted with regard to the recurrence rate between the MP1 and MP-groups, with cumulative incidences of 36% and 38%, respectively (Fig. 4) .
There was a trend toward a lower cumulative incidence of chronic GVHD in the MP1 group (36% vs 48%; P 5 .17) (Fig. 5) . The prevalence of chronic GVHD was found to be significantly (P 5 .031) lower in the MP1 group (Fig. 6) . Among the surviving patients, no patient who received MP but 28% of patients who did not receive MP were found to have active chronic GVHD at 10 years. Seven patients in each group developed a secondary malignancy; 1 patient in the MP1 group had 2 secondary tumors. Among patients in the MP1 group, the malignant tumors were breast cancer in 2 patients, lung cancer in 1 patient, esophageal cancer in 1 patient, prostate cancer in 2 patients, uterine cancer in 1 patient, and basalioma in 1 patient. Among patients in the MP-group, 2 patients had lung cancer, 1 patient had esophageal cancer, 1 patient had pancreatic cancer, 1 patient had colon cancer, and 2 patients had basalioma.
At 15 years, the survival rates were 55% in the MP1 group and 47% in the MP-group, and the nonrecurrence mortality rates were 21% and 30%, respectively. Thereafter there was marked nonrecurrence mortality in the MPgroup, 11 patients died after this time point, whereas there were no deaths during this period in the MP1 arm (Figs. 1 and 3) . At the end of follow-up, the overall survival rates in the MP1 and MP-groups were 55% and 20%, respectively, and the recurrence-free survival rates were 49% and 15%, respectively. The causes of the late death in the MP-group were bacterial infection in 3 patients, obstructive bronchiolitis in 1 patient, acute myocardial infarction in 1 patient, intracerebral bleeding in 1 patient, sudden death of unknown cause in 1 patient, lung cancer in 2 patients, esophageal cancer in 1 patient, and colon cancer in 1 patient.
Of the 11 patients who died >15 years after the transplantation, 9 had had chronic GVHD. Of the remaining 2 patients, 1 died suddenly of an unknown cause and the other died of a bacterial infection.
DISCUSSION
We observed marked nonrecurrence mortality after 15 years of follow-up in the MP-group whereas there were no deaths reported during this period in the MP1 group. The main causes of death among the 11 patients who died were secondary cancer in 4 patients, infection in 3 patients, most likely cardiovascular cause in 3 patients, and obstructive bronchiolitis in 1 patient.
The causes of the higher late mortality in the MPgroup are not fully obvious. However, the higher prevalence of chronic GVHD during the first 10 years may indicate a role for chronic GVHD. Nine of the 11 patients who died >15 years after undergoing transplantation had had chronic GVHD. Immune deficiency associated with chronic GVHD is a major cause of morbidity and mortality from infections. 23 Chronic GVHD has been shown to be a risk factor for secondary malignancy, [24] [25] [26] and active chronic GVHD is associated with an increased risk of cardiovascular morbidity and mortality. 23, 27 Reports on the long-term consequences of prophylactic corticosteroid administration are few. In a study comparing cyclosporine and MP with cyclosporine only in GVHD prophylaxis, Deeg et al 28 failed to demonstrate any significant long-term advantage for the addition of MP to cyclosporine. In that study, the median follow-up was 6 years. We observed significant differences between the outcomes of the study groups after 15 years; to our knowledge, no similar studies with comparable followups have been reported to date.
The role of corticosteroids in the prevention of GVHD remains unclear. The inconsistent results from studies regarding the effects of prophylactic corticosteroids in combination with the standard regimen of cyclosporine and a short course of methotrexate may be due to different administration schedules. In a randomized study, Storb et al 12 found that the addition of MP to the combination of cyclosporine and methotrexate increased the incidence of acute GVHD. In that study, MP was initiated on the day of transplantation and continued until day 35. If corticosteroid treatment was postponed until day 15, no increase in acute GVHD was observed. In another randomized study using a similar schedule, the addition of MP to cyclosporine and methotrexate was found to have no significant effect on GVHD. 13 In our randomized prospective study, 15 the administration of MP was initiated after the methotrexate treatment, on day 14, and continued until day 110. In this study, the addition of MP resulted in a significantly reduced incidence of acute GVHD, shorter hospitalization, and fewer infections, as well as a clear trend toward a lower incidence of chronic GVHD among low-risk patients. There were no differences in the rate of disease recurrence or survival. Using a similar administration schedule in a nonrandomized study, Hoyt et al 14 found that the addition of prednisolone to cyclosporine and methotrexate delayed the Figure 5 . Cumulative incidence of chronic graft-versus-host disease in patients given or not given methylprednisolone (MP). MP1 indicates patients who were given methylprednisolone; MP-, patients who were not given methylprednisolone. Figure 6 . Prevalence of chronic graft-versus-host disease in patients given or not given methylprednisolone (MP). MP1 indicates patients who were given methylprednisolone; MP-, patients who were not given methylprednisolone.
onset of acute GVHD in patients undergoing peripheral blood stem cell transplantation but had no impact on the overall incidence of GVHD. Thus, in our study, the corticosteroid prophylaxis was initiated later (after the completion of the standard short course of methotrexate) and continued longer than in the studies of Storb et al 12 and Atkinson et al, 13 which may have played a role in the different outcomes.
In the current study, there was a trend toward a lower cumulative incidence of chronic GVHD among the patients treated with MP. The prevalence of chronic GVHD during the first 10 years was significantly lower in the MP1 group. In some other studies, the incidence of chronic GVHD has been reported to be increased among patients treated with MP in addition to cyclosporine and methotrexate 12 or to cyclosporine 8 for prophylaxis. The causes of these unexpected findings and the difference from those of the current study are not clear, but possible factors are the marked reduction of acute GVHD in our study as well as the duration of MP prophylaxis. We administered MP until day 110 after transplantation, whereas the administration of MP was discontinued on day 35 in the study by Storb et al 12 and on day 72 in the study by Deeg et al. 8 The current long-term follow-up study has some obvious limitations when interpreting the results from today's perspective. The follow-up times were very long, and many practices in the transplantation procedures have changed since the active phase of the previous study. Our policy to treat patients with acute GVHD was aggressive, with early onset of treatment even in patients with lowgrade GVHD and initially higher doses of corticosteroid than recommended at present. The diagnosis of GVHD has developed, as well as the evaluation of disease recurrence, particularly of minimal residual disease. In this follow-up study, we used the same criteria as in the original publication 15 to maintain consistency and also because of the limitations of the data available from the later years of follow-up. Because the endpoints were robust and the follow-ups were long, the mentioned limitations in diagnostics are not likely to have essentially affected the main findings of the study.
The results of the current study indicate that adding corticosteroids to the conventional prophylaxis regimen of cyclosporine and methotrexate may have a beneficial effect on long-term survival, most likely by reducing chronic GVHD and its consequences. In the light of the manifold adverse effects of chronic GVHD, this observation is not surprising, and it may provide a reason for reconsidering prophylaxis regimens.
In a similar setting, antithymocyte globulin added to cyclosporine and methotrexate has been shown to reduce the incidence of chronic GVHD in patients who underwent transplantations from human leukocyte antigenidentical sibling 29 and unrelated 30 donors. The outcomes of the patients in these studies, after follow-up times similar to those of the current study, will be of significant interest. Novel agents, such as Janus kinase (JAK) inhibitors and ibrutinib, should be tested in a similar design in prospective trials.
The addition of corticosteroids to cyclosporine and methotrexate in GVHD prophylaxis, resulting in a marked decrease in the incidence of acute GVHD, also improved long-term survival. Nonrecurrence mortality was found to be reduced compared with the control group, whereas there was no difference noted with regard to the rate of disease recurrence. There was marked late nonrecurrence mortality in the group not given MP, which was possibly contributed to by the higher prevalence of chronic GVHD. The findings of the current study may support the re-evaluation of the role of corticosteroids in GVHD prophylaxis, as also suggested in another transplantation setting: haploidentical transplantation. 31 
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